Showing 571 - 580 of 1,415
In recent years, several countries have experienced increases in the incidence of serogroup C meningococcal disease. It can be controlled with older polysaccharide vaccines and particularly the recently developed conjugate vaccines. For 21 developed countries, we investigated the role that...
Persistent link: https://www.econbiz.de/10005404941
To support decision making, many countries have now introduced some formal assessment process to evaluate whether health technologies represent good `value for money'. These often take the form of decision models that can be used to explore elements of importance to generalisability of study...
Persistent link: https://www.econbiz.de/10005404948
The broad availability of genetic information and technologies heralds an era when practitioners will utilise genomic testing to individualise patients Assessing the incremental cost effectiveness of a pharmacogenomic strategy involves examination of factors associated with the genotype of...
Persistent link: https://www.econbiz.de/10005404955
Persistent link: https://www.econbiz.de/10005404959
Worldwide, major depression is the leading cause of years lived with a disability, and the fourth cause of disability-adjusted life years. Depression is second only to hypertension as the most common chronic condition encountered in general medical practice. Unfortunately, despite the high...
Persistent link: https://www.econbiz.de/10005404970
Objective: The aim of this study was to determine the cost effectiveness of 2 inhaled corticosteroids, fluticasone propionate and flunisolide, in the management of asthma from a third-party payer perspective in Germany (German Sickness Fund). Design and setting: Direct treatment costs were...
Persistent link: https://www.econbiz.de/10005404975
Persistent link: https://www.econbiz.de/10005404988
People receiving a renal transplant require long-term treatment with immunosuppressant drugs. Contemporary regimens usually include a calcineurin inhibitor (CI), either ciclosporin or tacrolimus, in conjunction with at least one other drug. The aim of this study was to review the economic...
Persistent link: https://www.econbiz.de/10005404995
Persistent link: https://www.econbiz.de/10005404997
In this review, the economic aspects of pneumococcal pneumonia are analysed, including the costs, cost effectiveness and cost benefit of treatment and prevention. We identified eight cost-of-illness studies, 15 analyses comparing the costs of different treatment options and 15 economic...
Persistent link: https://www.econbiz.de/10005404998